Premium
Roxatidine versus ranitidine in the treatment of duodenal ulcers: A randomized double‐blind controlled multicentre study in Singapore
Author(s) -
FOCK KM,
KANG JY,
NG HS,
NG TM,
GWEE KA,
LIM CC
Publication year - 1995
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.1995.tb01587.x
Subject(s) - ranitidine , medicine , bedtime , histamine h2 receptor , gastroenterology , randomized controlled trial , antagonist , anesthesia , receptor
Roxatidine acetate, a new H 2 receptor antagonist, was compared with ranitidine in the treatment of duodenal ulcers in a double‐blind multicentre study. Eighty‐four patients with endoscopically proven duodenal ulcer were randomized to receive 150 mg roxatidine acetate or 300 mg ranitidine at bedtime. Repeat endoscopy was performed after 4 weeks (25–33 days) and if the ulcer had not healed, another endoscopy was performed after a further 4 weeks of treatment. Using per protocol analysis 73.6% of ulcers treated with roxatidine healed at 4 weeks compared to 72.2% of ulcers treated with ranitidine ( P =NS). The healing rates at 8 weeks were 92% with roxatidine and 83.3% with ranitidine ( P =NS). Using equivalence tests, the healing rate of roxatidine was found to be equivalent to that of ranitidine within a 20% region. Roxatidine users took significantly less antacids than ranitidine users ( P < 0.05). There were no significant adverse effects due to roxatidine or ranitidine. Roxatidine is a safe effective drug in the treatment of duodenal ulcers with a healing rate comparable to that of ranitidine.